Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
I-125 sodium iodide is a high-purity radiochemical and radiopharmaceutical precursor produced by the Institute of Isotopes Co. (Izotop). It consists of the radioisotope iodine-125 in the form of sodium iodide, supplied as a clear, colorless solution in dilute sodium hydroxide. I-125 decays via electron capture with a half-life of approximately 59.4 days, emitting low-energy gamma radiation (35 keV) and characteristic X-rays. While primarily used as a precursor for labeling compounds in research and pharmaceutical manufacturing, I-125-labeled products are utilized in brachytherapy for various cancers (including prostate cancer, uveal melanomas, and brain tumors), in vitro diagnostic assays such as radioimmunoassays, and diagnostic procedures such as glomerular filtration rate (GFR) measurement for kidney disease assessment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on I-125 sodium iodide (Izotop).